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patients with multiple myeloma (MM). Combining standard frac-
tionated total body irradiation (TBI) with high-dose melphalan
precludes optimal dosing of melphalan, and results in equivalent
efﬁcacy but more toxicity in comparison to high-dose melphalan
(mel) alone. Helical tomotherapy is a novel tool for delivering CT
image guided intensity modulated radiation therapy and may allow
for greater doses of total marrow irradiation (TMI) and less col-
lateral damage to other organs. We set out to test the feasibility of
THDT inclusive of TMI. Eligible patients (70 years old, with
stages I-III MM, in response or with stable disease, with a creati-
nine clearance of 50 mL/min) underwent mobilization with cy-
clophosphamide 1.5 gm/m2 and G-CSF 10 microgram/kg and
procurement of  4  106 CD34 cells/kg. THDCT consisted
of a set dose of mel 200 mg/m2 followed by PBPC. At a
minimum of 6 weeks later, TMI 200 cGy daily  5 days, (to be
escalated up to 200 cGy twice daily in a standard phase one
cohort by cohort fashion) an PBPC is administered. Upon
recovery, thalidomide 50–200 mg daily and dexamethasone 40
mg/day  4 days every 28 days is to be prescribed. At dose level
1 (TMI: 200 cGy daily  5 days ) two patients (a 53 year old
female with stage I MM in complete response and a 48 year old
male with stage III MM in partial response prior to THDT)
have completed THDT and are currently receiving mainte-
nance. Neutrophyl and platelet recovery following TMI was
observed by days 9 and 11, and platelet independence (deﬁned as
the day after the last platelet transfusion) was observed by day
10. Grade 1 emesis and grade 2 nausea, but no evidence of oral
mucositis, enteritis, or skin erythema were noted. The estimated
reduction in organ exposure to radiation with TBI versus TMI
ranged from 6.5–6.9-fold (lens) to 2.5–2.6-fold (bowel), and
1.4–1.7-fold (lungs) in the ﬁrst two patients treated. TMI is
feasible for patients undergoing THDT for MM. Accrual is
ongoing and results in patients treated at higher doses of TMI
will be presented.
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COMPARISON OF CD34 COLLECTIONS IN PATIENTS WITH MUL-
TIPLE MYELOMA USING ETOPOSIDE/CYCLOPHOSPHAMIDEGCSF,
CYCLOPHOSPHAMIDEGCSF, AND GCSF ALONE MOBILIZATION
REGIMENS
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Saracino, G.1, Agura, E.D.1, Berryman, R.B.1, Fay, J.W.1,
Pineiro, L.1, Vance, E.A.1 1Baylor Sammons Cancer Center, Baylor
University Medical Center, Dallas, TX.
Introduction: Low risk, curative therapy for patients with
multiple myeloma remains elusive. Autologous stem cell trans-
plant remains the standard of care for newly diagnosed multiple
myeloma. Mobilization of adequate CD34 cells can be a dif-
ﬁcult task, especially in patients who have been heavily pre-
treated. We have compared the three mobilization regimens
utilized at our facility and the subsequent CD34 collections.
Background: Standard chemotherapy is effective in maintain-
ing control of multiple myeloma, however none has proven
curative. Several trials have indicated that tandem or double
autologous transplants may provide a signiﬁcant beneﬁt for
overall survival and event free survival. When double trans-
plants are planned, especially for patients who are heavily pre-
treated, collection of adequate CD34 cells can prove to be
challenging. Methods: 217 patients with multiple myeloma
whose treatment plan included either a single or double autol-
ogous transplant were evaluated retrospectively. Data have been
collected from January 1999 to March 2005. Mobilization reg-
imens utilized were etoposide/cyclophosphamideGCSF,
60 patients; cyclophosphamideGCSF, 34 patients; and
GCSF alone, 123 patients. Peripheral blood stem cells were
collected following standard institutional procedures utilizing
the Cobe Spectra apheresis machine. Standard CD34 cell dose
target for a single transplant was 	2.0  106/kg. Results:
Average and median CD34 cell dose collected for patients
receiving GCSF alone was 24.05  106/kg and 6.3  106/kg;
cyclophosphamideGCSF 13.28  106/kg and 9.75  106/kg;
etoposide/cyclophosphamideGCSF 39.98  106/kg and
30.4  106/kg. The average number of collections required
for each regimen was 2.11 days for GCSF, 1.76 days for
cyclophosphamideGCSF, and 1.4 days for etoposide/cyclophosph-
amideGCSF.Conclusions: Etoposide/cyclophosphamideGCSF
mobilization regimen is highly effective in mobilizing large numbers
of CD34 cells in multiple myeloma patients making double or
tandem transplants a viable treatment option.
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A PILOT STUDY OF CYCLOPHOSPHAMIDE, CARBOPLATIN, ETOPOSIDE
(CCE), AND G-CSF WITH OR WITHOUT RITUXIMAB FOR CYTOREDUC-
TION AND PERIPHERAL BLOOD STEM CELL MOBILIZATION IN PA-
TIENTS WITH RELAPSED OR REFRACTORY LYMPHOMAS
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Ornstein, D.L.2, Heller, B.J.3 1. Wilford Hall Medical Center, Lack-
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Background: Salvage chemotherapy is used for cytoreduction
and PBSC mobilization in patients with relapsed and refractory
lymphomas. Hospitalization is generally required for administra-
tion of the most commonly used regimens. We conducted a pilot
study to determine the feasibility of delivering CCE with or with-
out rituximab for cytoreduction and chemomobilization entirely in
the outpatient setting to patients with refractory or recurrent
non-Hodgkin’s or Hodgkin’s lymphoma who were candidates for
high dose therapy with autologous stem cell support. Methods: 2
cycles of CCE were administered at 21 day intervals. The regimen
consisted of cyclophosphamide 1 gram/m2 on day 1, carboplatin at
an AUC of 5 on day 2, and etoposide 100 mg/m2 on days 1, 2, and
3. G-CSF, 5 mcg/kg/day was administered on days 512 with
cycle 1 and the dose was increased to 10 mcg/kg/day for PBSC
mobilization with cycle 2. After the ﬁrst 8 patients, the protocol
was amended to allow the use of rituximab at a dose of 375
mg/m2on days 1, 8, and 15 of each cycle for those patients with
CD20 lymphomas. Results: 18 patients have been enrolled and
have completed CCE. The diagnoses include B-cell non-
Hodgkin’s lymphoma (B-NHL; n  8 large cell, n  2 follicular),
Hodgkin’s lymphoma (n  3), peripheral T-cell lymphoma (n 
2), anaplastic large cell lymphoma (n  1), composite B-NHL/
Hodgkin’s lymphoma (n  1), and T-cell rich, B-cell lymphoma
(n  1). The median age was 46 years (range 19–69). One patient
received one cycle of CCE, while 2 patients received more than 2
cycles. The overall response rate for the regimen is 63% (3 CR, 7
PR, 5 SD, 1 PD, 2 not evaluable). PBSC were collected successfully
from 16/18 patients. The median number of PBSC collected was
7.5  106 CD34 cells/kg (range 2.1–16.8  106), and the median
number of apheresis sessions was 2 (range 1–9). There were 4
hospitalizations for neutropenic fever in 38 cycles. Non-hemato-
logic toxicity was minimal, and no deaths occurred on study. All
patients from whom sufﬁcient PBSC were collected underwent
high dose therapy with autologous PBSC rescue, and hematologic
recovery occurred in 100%. Conclusions: The interim results of
this pilot study suggest that CCE is a safe and effective outpatient
regimen for cytoreduction and PBSC mobilization for relapsed or
refractory non-Hodgkin’s and Hodgkin’s lymphoma. This regi-
men warrants further study, and a total of 30 patients will be
enrolled on this continuing study.
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SALVAGE AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA
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Giralt, S.A.1 1University of Texas-M. D. Anderson Cancer Center,
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Introduction: Most patients undergoing high-dose therapy and
autologous transplant for multiple myeloma eventually relapse.
The optimal treatment for these patients is still evolving. There
have been few reports of autologous transplants in the salvage
setting. We analyzed the outcome of salvage autologous transplant
in 22 patients with disease progression after the ﬁrst autograft.
Methods: These patients in general were not eligible for an allo-
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geneic transplant due to older age, comorbidities or lack of HLA-
identical donor. Median age at transplant was 52 years (range
37–68), median interval between ﬁrst and second autograft was 26
months (range 3–73). Eleven patients had persistent or progressive
disease at transplant. Twenty patients received high-dose melpha-
lan alone or in combination, while 2 received a combination of
thiotepa, busulfan and cyclophosphamide. Patients had received an
average of 6 prior chemotherapy regimens. Cytogenetic studies
were available in 18/22 patients at the time of transplant, 12 were
normal and 6 abnormal. Results: 14 of the 21 evaluable patients
(70%) achieved a response (1 CR, 13 PR). After a median fol-
low-up of 15 months (2–82), 1 year progression-free survival (PFS)
was 40% and 1-year overall survival (OS) was 78%. 100-day TRM
was 0%. Median PFS was 10 months, and median OS has not been
reached. On univariate analysis, abnormal cytogenetics at trans-
plant was a predictor of shorter overall survival (P  .01). Con-
clusions: In patients with progressive disease after an autologous
transplant, salvage autologous transplants may achieve responses in
70% of patients with durable remissions in a small subset. Normal
cytogenetics at second transplant predicts a longer survival.
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AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN
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Background: Autologous peripheral blood stem cell transplan-
tation is at the present the therapy of choice for the treatment of
multiple myeloma (MM) patients younger than 70 years old.
Methods: Between August 1993 and November 2004, ﬁfty four
patients with MM were autografted; median age was 49 years
(range 20–69). Patients were given a median of 4.3  106/Kg
CD34 () viable MNC after conditioning with high-dose melpha-
lan regimens (oral or I.V. in 47 and 7 patients, respectively).
Results: Median time to achieve 	 0.5  109/L granulocytes was
12 days, whereas median time to achieve 	20  109/L platelets
was 15 days. Thirty seven patients are alive 15 to 157 months after
the autograft (median 86 months). The 7-year disease-free and
overall post-transplant survival is 24% and 60%, respectively. The
transplant-related mortality was 13%. Seven patients died as a
result of the toxicity of the conditioning regimen, whereas death in
the remaining 10 cases was related to post-transplant relapse of the
malignancy. Four good-prognostic factors were identiﬁed: interval
between diagnosis and transplant less than 24 months, number of
prior chemotherapy regimens 2, remission status (complete or
partial), and pretransplant 2microglobulin less than 3 mg/dL.
Conclusions: Autologous peripheral blood stem cell transplanta-
tion using oral melphalan was a good choice of treatment for
Mexican multiple myeloma patients. Transplant-related mortality
was higher in comparison with other studies.
350
DRAMATIC IMPROVEMENT OF POEMS SYNDROME BY STEM CELL
TRANSPLANTATION PARALLELS DECREASE IN VEGF AND BFGF LEVEL
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Purpose: POEMS syndrome is a rare disease characterized by
polyneuropathy, organomegaly, endocrinopathy, M-protein, and
skin changes. We treated a severely ill woman with a 4-year history
of polyneuropathy showing all signs of a POEMS syndrome. Re-
sponse to chemotherapy including high-dose melphalan treatment
and autologous stem cell transplantation was monitored and vas-
cular endothelial growth factor (VEGF) as well as basic ﬁbroblast
growth factor (bFGF) levels were measured. Methods: Blood
investigation was done for serum electrophoresis analysis and anal-
ysis of VEGF, bFGF, and IL-6 by ELISA. Bone marrow biopsy
specimen was investigated immunohistochemically for IgA, IgG,
kappa, lambda, CD20, CD56, cyclin D1, and VEGF. Results:
Immunohistochemical investigation of the bone marrow biopsy
showed an inﬁltration of IgA and lambda positive plasma cells
(10%). Only few plasma cells expressed kappa. The tumor cell were
negative for CD20, CD56, and cyclin D1, but positive for VEGF
in line with the high VEGF levels in the blood. Blood investigation
revealed a discrete monoclonal gammopathy of IgA lambda type.
Initially, high level of VEGF (1468.7 pg/ml) and bFGF (112.9
pg/ml) were detected. However, treatment with high-dose mel-
phalan and tandem autologous stem cell transplantation proved
extremely helpful in disease control. Already after the ﬁrst trans-
plant the patient started again walking and lost her pulmonary
hypertension. In parallel VEGF and bFGF levels decreased and the
performance status of the patient improved dramatically. Conclu-
sions: VEGF and bFGF measurement is a useful tool for moni-
toring disease activity in POEMS syndrome. Moreover, although
stem cell transplantation is of utmost importance even in patients
with severely reduced performance status, these pathophysiologic
ﬁndings may provide a rational for additional treatment ap-
proaches with anti-angiogenetic substances.
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BONE MARROW TRANSPLANTATION FROM MATCHED UNRELATED DO-
NORS FOR PATIENTS WITH SEVERE COMBINED IMMUNE DEFICIENCY
Grunebaum, E.1, Atkinson, A.R.1, Reid, B.1, Roifman, C.M.1 1Hospital
for Sick Children, Toronto, ON, Canada.
Introduction: Bone Marrow Transplant (BMT) from related
HLA identical donor (RID) is the treatment of choice for patients
with severe combined immuno-deﬁciency (SCID). In the absence
of RID, bone marrow from HLA haplo-identical (half) related
donors (HID) have often been used. However, HID is frequently
associated with reduced survival and failure of long-term immune
reconstitution. HLA matched unrelated donors (MUD) represent
another promising alternative for patients with SCID. Methods:
We studied hematopoietic engraftment, occurrence of graft versus
host disease, infections and other complication, and survival in
infants diagnosed with SCID who received MUD BMT between
1990 and 2004 in a Canadian pediatric referral center specializing
in such procedures. Detailed evaluations of immune reconstitution
were performed in children that survived more than 2 years after
transplant. Results: During the 14 years of this study, 22 infants
underwent MUD BMT in our center. Molecular diagnosis was
available in 64% of them. All infants received myelo-ablative con-
ditioning pre-transplant. Despite prophylaxis with cyclosporine
and methylprednisolone, acute graft versus host disease occurred in
15 of the 22 patients, and it was the most common cause of death.
All patients developed complete donor lymphocyte engraftment.
None of the 15 patients who are two or more years after transplant
requires intravenous immunoglobulin replacement therapy. After
discontinuing immune suppression all patients have normal T cell
function and T cell repertoire, which is sustained for more than 14
years of follow up. Current survival is 73% and it is even better for
patients with mutations in the IL-2 receptor pathway. Further-
more, survival of patients who presented with low B cells, previ-
ously estimated to have unfavorable outcome, is not signiﬁcantly
lower than in other forms of SCID in this study. Conclusions:
MUD BMT leads to long term survival, engraftment, and immune
function in SCID patients and should be the preferred treatment
for clinically stable infants who do not have a related HLA-iden-
tical donor.
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